A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation studyJesse J. Swen, Roelof Bosch, Cathelijne H. van der Wouden et al.|The Lancet|2023Cited by 508
Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus documentMarieke Biegstraaten, Carla E. M. Hollak, Dominique P. Germain et al.|Orphanet Journal of Rare Diseases|2015Cited by 345
Effect of High Dose Folic Acid Therapy on Hyperhomocysteinemia in Hemodialysis PatientsGere Sunder–Plassmann, Walter H. HoCombining Diaeresisrl, Heidi Buchmayer et al.|Journal of the American Society of Nephrology|2000Cited by 125
Severe nephrotic syndrome and early end-stage diabetic kidney disease in ABCC8-MODY12: A case reportSophie Schmidt, Gere Sunder–Plassmann, Ursula Barnas et al.|Frontiers in Genetics|2023Cited by 3